Key Points
- CFO Hunter Smith sold 2,766 shares on Feb. 11 at an average price of $98.61 for a total of $272,755.26, trimming his stake by 2.25% to 120,058 shares (about $11.84M).
- Rhythm stock opened at $96.06 and was down about 2.4%, with a 52‑week range of $45.90–$122.20, a market cap of roughly $6.41B and a negative P/E of about -30.99.
- Analysts are generally bullish (majority Buy ratings) with an average price target of $131.29, and several firms (Goldman Sachs, Wells Fargo, Citizens JMP) recently raised their targets.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter Smith sold 1,592 shares of the business's stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $98.23, for a total value of $156,382.16. Following the completion of the transaction, the chief financial officer directly owned 118,466 shares of the company's stock, valued at $11,636,915.18. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Rhythm Pharmaceuticals Price Performance
NASDAQ:RYTM opened at $96.06 on Friday. The company has a 50 day moving average price of $106.28 and a 200-day moving average price of $102.72. Rhythm Pharmaceuticals, Inc. has a 1-year low of $45.90 and a 1-year high of $122.20. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of -30.99 and a beta of 2.00.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of RYTM. Xponance LLC raised its stake in Rhythm Pharmaceuticals by 2.6% in the fourth quarter. Xponance LLC now owns 4,269 shares of the company's stock valued at $457,000 after buying an additional 107 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Rhythm Pharmaceuticals by 4.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company's stock valued at $259,000 after buying an additional 110 shares during the last quarter. Captrust Financial Advisors lifted its position in Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company's stock valued at $1,104,000 after purchasing an additional 114 shares during the period. GAMMA Investing LLC raised its position in Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company's stock worth $39,000 after acquiring an additional 118 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company's stock valued at $29,000 after purchasing an additional 141 shares in the last quarter.
Analyst Ratings Changes
Several brokerages recently weighed in on RYTM. HC Wainwright lifted their price target on Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the company a "buy" rating in a research note on Tuesday, January 20th. Guggenheim increased their target price on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, December 17th. Wall Street Zen cut shares of Rhythm Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Canaccord Genuity Group boosted their price target on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a "buy" rating in a report on Friday, December 12th. Finally, Needham & Company LLC boosted their price objective on Rhythm Pharmaceuticals from $145.00 to $148.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $131.29.
View Our Latest Stock Analysis on Rhythm Pharmaceuticals
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
